title: Correlation between 18F-FDG-uptake and in vitro chemosensitivity of cisplatin in head and neck cancer.
abstract: OBJECTIVE
  High [18F]-2-fluorodeoxyglucose (18F-FDG) -uptake of primary tumor, assessed by pretreatment positron emission tomography combined computed tomography (PET/CT), has indicated poor overall survival (OS) in head and neck cancer (HNC).We investigated the correlation between 18F-FDG-uptake and in vitro chemosensitivity of cisplatin using histoculture drug response assay in HNC.
  
  
  METHODS
  Twenty-eight patients were evaluated. The maximum standardized uptake value (SUVmax) and inhibition index (I.I.) cisplatin were calculated as 18F-FDG-uptake and in vitro chemosensitivity of cisplatin.
  
  
  RESULTS
  Each SUVmax10.5 or I.I.cisplatin<50 could significantly differentiate shorter survival group by OS analyses. I.I.cisplatin of patients with SUVmax≥10.5 was significantly greater. In 19 patients with SUVmax≥10.5, those who received treatment with cisplatin-based chemotherapy exhibited a significant correlation with longer OS.
  
  
  CONCLUSIONS
  Cisplatin hasthe potential to improve OS for HNC patients that were predicted as shorter OS by 18F-FDG-PET/CT.
authors: Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan hi.suzuki@aichi-cc.jp.
authors: Hidenori
authors: H
authors: Suzuki
authors: Department of Radiology, Nagoya PET Imaging Center, Nagoya, Japan.
authors: Masami
authors: M
authors: Nishio
authors: Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
authors: Nobuhiro
authors: N
authors: Hanai
authors: Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
authors: Hitoshi
authors: H
authors: Hirakawa
authors: East Nagoya Imaging Diagnosis, Nagoya, Japan.
authors: Tsuneo
authors: T
authors: Tamaki
authors: Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
authors: Yasuhisa
authors: Y
authors: Hasegawa
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002945:Cisplatin / Q000494:pharmacology*; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D006258:Head and Neck Neoplasms / Q000473:pathology*; D006801:Humans; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D016019:Survival Analysis; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D019788:Fluorodeoxyglucose F18; D002945:Cisplatin
keywords: 18F-FDG-PET/CT; Head and neck cancer; SUVmax; inhibition index cisplatin; overall survival